All Stories

  1. Effect of IV ferric carboxymaltose treatment on platelet counts and serum transferrin levels in CKD patients not on dialysis with iron deficiency: potential implications for thrombogenicity
  2. International Environmental Impact of CKD Care
  3. KDIGO 2026 clinical practice guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP)
  4. Changes in platelet count as a marker of myocardial iron uptake after administration of ferric carboxymaltose in patients with heart failure
  5. Interaction Between Frailty and Renal Function in Patients with Heart Failure
  6. The Role of Albuminuria in Diagnosing and Stratifying Kidney Disease in Heart Transplant Recipients: A KDIGO Criteria‐Based Analysis
  7. Anemia and iron deficiency in post-kidney transplantation: an unsolved challenge
  8. Anemia Management in the Cardiorenal Patient: A Nephrological Perspective
  9. Systemic inflammation prevalence in patients with atherosclerotic cardiovascular disease and chronic kidney disease: a population-based study using a nationwide primary care database in Spain
  10. Gut Dysbiosis and Its Role in the Anemia of Chronic Kidney Disease
  11. Using Chronic Kidney Disease as a Model Framework to Estimate Healthcare-Related Environmental Impact
  12. Cardiovascular-kidney-metabolic syndrome definition and its role in the prevention, risk staging, and treatment. An opportunity for the Nephrology
  13. La definición del síndrome cardiovascular-reno-metabólico (cardiovascular-kidney-metabolic syndrome) y su papel en la prevención, estatificación del riesgo y tratamiento. Una oportunidad para la Nefrología
  14. Effect of SGLT2 inhibitors on anemia and their possible clinical implications
  15. Efecto de los inhibidores del cotransportador sodio-glucosa tipo 2 sobre la anemia: posibles implicaciones clínicas
  16. Fibrilación auricular no valvular en pacientes en diálisis peritoneal: prevalencia, tratamiento y profesionales implicados
  17. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations
  18. The ERA Registry Annual Report 2021: a summary
  19. Gender-specific risk factors and outcomes of hyperkalemia in CKD patients: smoking as a driver of hyperkalemia in men
  20. 236.2: Simultaneous kidney-pancreas transplantation improves endothelial dysfunction induced by extracellular vesicles
  21. Unresolved aspects in the management of renal anemia, a Delphi consensus of the Anemia Group of the S.E.N
  22. Reticulocyte hemoglobin content and iron therapy in chronic kidney disease: Reply of the Anemia group of the Spanish Society of Nephrology
  23. Epidemiology and treatment of renal anaemia in Spain: RIKAS retrospective study
  24. Epidemiología y tratamiento de la anemia renal en España: estudio retrospectivo RIKAS
  25. Concentración de hemoglobina reticulocitaria y ferroterapia en la enfermedad renal crónica: respuesta del grupo de Anemia de la Sociedad Española de Nefrología
  26. Aspectos no resueltos en el manejo de la anemia renal, un consenso Delphi del Grupo de Anemia de la S.E.N
  27. Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist
  28. Opportunities to improve the management of anemia in peritoneal dialysis patients: lessons from a national study in routine clinical practice
  29. Gout Prevalence, Practice Patterns, and Associations with Outcomes in North American Dialysis Patients
  30. Agonistas del receptor de péptido similar al glucagón tipo 1 (GLP-1) en el manejo del paciente con diabetes mellitus tipo 2. Una aproximación para el nefrólogo
  31. Impacto pronóstico de la enfermedad renal crónica sobre el cierre percutáneo de la orejuela izquierda en la fibrilación auricular: una experiencia unicéntrica
  32. Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving Dialysis
  33. Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients
  34. Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
  35. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis
  36. Iron Deficiency in CKD Without Concomitant Anemia
  37. Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review
  38. Worldwide Early Impact of COVID-19 on Dialysis Patients and Staff and Lessons Learned: A DOPPS Roundtable Discussion
  39. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
  40. Aplastic crisis secondary to parvovirus B19 primoinfection as an infrequent cause of anemia in an immunocompetent, non-dialysis chronic kidney disease patient
  41. Medical Director Practice of Advising Increased Dietary Protein Intake in Hemodialysis Patients With Hyperphosphatemia: Associations With Mortality in the Dialysis Outcomes and Practice Patterns Study
  42. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents
  43. Ferroterapia en el manejo de la anemia en la enfermedad renal crónica no en diálisis: perspectiva del grupo de anemia de la S.E.N
  44. Iron replacement therapy in the management of anaemia in non-dialysis Chronic kidney disease patients: Perspective of the Spanish Nephrology Society Anaemia Group
  45. Effect of comorbidities on survival in patients >80 years of age at onset of renal replacement therapy: data from the ERA-EDTA Registry
  46. Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality
  47. SARS-CoV-2 Infection in a Spanish Cohort of CKD-5D Patients: Prevalence, Clinical Presentation, Outcomes, and De-Isolation Results
  48. Beta-2 microglobulin and all-cause mortality in the era of high-flux hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study
  49. Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia
  50. Endothelial Damage, Inflammation and Immunity in Chronic Kidney Disease
  51. Data from the ERA-EDTA Registry was examined for trends in excess mortality in European adults on kidney replacement therapy.
  52. Up‐regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide
  53. Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry
  54. Percutaneous Left Atrial Appendage Closure, A Safe Alternative To Anticoagulation For Patients With Non‐Valvular Atrial Fibrillation And End‐Stage Renal Disease On Hemodialysis: A Single Center Experience
  55. Sex Differences in Kidney Replacement Therapy Initiation and Maintenance
  56. Changes in clinical indicators related to the transition from dialysis to kidney transplantation—data from the ERA-EDTA Registry
  57. Vegetable-Based Diets for Chronic Kidney Disease? It Is Time to Reconsider
  58. Mortality due to bleeding, myocardial infarction and stroke in dialysis patients
  59. ¿Son seguros y eficaces los antiagregantes plaquetarios en los pacientes con insuficiencia renal?
  60. Changes in co-morbidity pattern in patients starting renal replacement therapy in Europe—data from the ERA-EDTA Registry
  61. Antioxidant and Anti-Inflammatory Strategies Based on the Potentiation of Glutathione Peroxidase Activity Prevent Endothelial Dysfunction in Chronic Kidney Disease
  62. Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology
  63. Anemia en la enfermedad renal crónica: protocolo de estudio, manejo y derivación a Nefrología
  64. Anemia en la enfermedad renal crónica: protocolo de estudio, manejo y derivación a Nefrología
  65. Anemia en la enfermedad renal crónica: protocolo de estudio, manejo y derivación a Nefrología
  66. Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia
  67. Prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
  68. Insuficiencia cardíaca en la enfermedad renal y déficit de hierro: importancia de la ferroterapia
  69. Heart failure in patients with kidney disease and iron deficiency: The role of iron therapy
  70. Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function
  71. TO021DIRECT FACTOR Xa INHIBITOR APIXABAN PREVENTS ENDOTHELIAL ACTIVATION AND DAMAGE ASSOCIATED WITH CHRONIC KIDNEY DISEASE
  72. Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: a cross-sectional analysis
  73. Gut microbiota in chronic kidney disease
  74. Enfermedad renal crónica y dislipidemia
  75. Microbiota intestinal en la enfermedad renal crónica
  76. Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study
  77. Delphi consensus on the diagnosis and management of dyslipidaemia in chronic kidney disease patients: A post hoc analysis of the DIANA study
  78. Consenso Delphi sobre el diagnóstico y manejo de la dislipidemia en pacientes con enfermedad renal crónica: análisis post-hoc del estudio DIANA
  79. Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study
  80. Consenso Delphi sobre el manejo de la dislipidemia en pacientes con alteración del metabolismo de la glucosa: estudio Diana
  81. Estudio EPRICS con eritropoyetina: otro intento fallido para evitar el daño renal poscirugía cardiaca
  82. WITHDRAWN: Estudio EPRICS con eritropoyetina: otro intento fallido para evitar el daño renal poscirugía cardiaca
  83. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis
  84. Carotid Atherosclerotic Disease Predicts Cardiovascular Events in Hemodialysis Patients: A Prospective Study
  85. FO020ENDOTHELIAL DYSFUNCTION IN UREMIA: EFFECT OF FLAVONOIDS AND ANTIOXIDANTS
  86. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease
  87. Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study1
  88. Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study1
  89. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
  90. TLR4 and NALP3 inflammasome in the development of endothelial dysfunction in uraemia
  91. Efficacy of a Simple Dosage Scheme to Convert From Shorter-acting Erythropoiesis-stimulating Agent to Continuous Erythropoietin Receptor Activator in Kidney Transplantation Patients
  92. Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study
  93. Sensitivity of Blood Volume Monitoring for Fluid Status Assessment in Hemodialysis Patients
  94. Evolution of the incidence of chronic kidney disease Stage 5 requiring renal replacement therapy in the diabetic population of Catalonia
  95. NFκB in the Development of Endothelial Activation and Damage in Uremia: An In Vitro Approach
  96. Relación del grado de control glucémico con las características de la diabetes y el tratamiento de la hiperglucemia en la diabetes tipo 2. Estudio DIABES
  97. Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in spain: the MERENA observational cohort study
  98. Nocturnal, every-other-day, online haemodiafiltration: an effective therapeutic alternative
  99. Endothelial Dysfunction in Chronic Renal Failure
  100. Respuesta
  101. Prevalence of Chronic Kidney Disease in Patients With or at a High Risk of Cardiovascular Disease
  102. Prevalencia de insuficiencia renal crónica en pacientes de alto riesgo o con enfermedad cardiovascular
  103. Response
  104. What Infusion Flow Should Be Used for Mid-Dilution Hemodiafiltration?
  105. Introducción
  106. Abordaje multidisciplinar de la enfermedad aterotrombótica
  107. Conclusiones
  108. Mid-Dilution Hemodiafiltration: A Comparison with Pre- and Postdilution Modes Using the Same Polyphenylene Membrane
  109. Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study
  110. In Vivo Evaluation of Platelet Activation by Different Cellulosic Membranes
  111. Prevalence and Clinical Characteristics of HIV Type 1-Infected Patients Receiving Dialysis in Spain: Results of a Spanish Survey in 2006: GESIDA 48/05 Study
  112. Influence of the Ionic Dialysance Monitor on Kt Measurement in Hemodialysis
  113. Mspl identifies a biallelic polymorphism in the promoter region of the α2A-adrenergic receptor gene
  114. Differential Expression of Proteins From Cultured Endothelial Cells Exposed to Uremic Versus Normal Serum
  115. Chronic hypotension in hemodialysis patients: role of functional vascular changes and vasodilator agents
  116. Effect of Two Different Dialysis Membranes on Leukocyte Adhesion and Aggregation
  117. Dyslipidemia and the progression of renal disease in chronic renal failure patients
  118. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study
  119. Cigarette smoke concentrate increases 8-epi-PGF2$alpha; and TGF$beta;1 secretion in rat mesangial cells
  120. The effects of smoking and its cessation on 8-epi-PGF2α and transforming growth factor-beta 1 in Type 1 diabetes mellitus
  121. Biocompatibility of Cellulosic and Synthetic Membranes Assessed by Leukocyte Activation
  122. Update in nephrology: Highlights from the 36th Annual Meeting of the ASN
  123. Interactions Between Vasoconstrictors and Vasodilators in Regulating Hemodynamics of Distinct Vascular Beds
  124. Uraemic medium accelerates proliferation but does not induce apoptosis of endothelial cells in culture
  125. Darbepoetin alfa: A novel erythropoiesis-stimulating protein
  126. Nonconvulsive status epilepticus in dialysis patients
  127. Morbimortalidad cardiovascular en la diabetes mellitus tipo 2
  128. Análisis de la frecuencia cardíaca como factor de riesgo asociado a la progresión de la insuficiencia renal crónica
  129. Erythropoietin Triggers a Signaling Pathway in Endothelial Cells and Increases the Thrombogenicity of their Extracellular Matrices In Vitro
  130. Effect of angiotensin II receptor blockade on renal disease progression in patients with non‐diabetic chronic renal failure
  131. Hemodynamic and renal effects of acute and progressive nitric oxide synthesis inhibition in anesthetized dogs
  132. Hipermineralocorticismo exógeno como causa de descompensación de una hipertensión esencial previamente controlada
  133. Mecanismos de desarrollo del daño vascular en pacientes en diálisis
  134. Uremic Medium Disturbs the Hemostatic Balance of Cultured Human Endothelial Cells
  135. Increased plasma adrenomedullin levels in hemodialysis patients with sustained hypotension
  136. Abnormal platelet cytoskeletal assembly in hemodialyzed patients results in deficient tyrosine phosphorylation signaling
  137. Papel de la adrenomedulina en el control de la presión arterial y la homeostasis del líquido extracelular
  138. Doxazosin in a gastrointestinal therapeutic system formulation
  139. Novel Erythropoiesis Stimulating Protein
  140. Recombinant human erythropoietin treatment in chronic renal failure: Effects on hemostasis and vasculature
  141. β-adrenergic receptor density and function in left ventricular hypertrophy in young essential hypertensives
  142. Smoking increases serum levels of transforming growth factor-beta in diabetic patients
  143. Clinical pharmacology of nebivolol
  144. Erythropoietin Improves Signaling through Tyrosine Phosphorylation in Platelets from Uremic Patients
  145. Lamifiban
  146. Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uremic patients: Association with early improvement in platelet function
  147. Renal Failure in Multiple Myeloma
  148. Platelet-Leukocyte Activation during Hemodialysis Detected with a Monoclonal Antibody to Leukocyte Integrin CD11b
  149. Advances in hypertension management: Update 1998
  150. Autonomic nervous system and adrenergic receptors in chronic hypotensive haemodialysis patients
  151. New Insights Into the Pathophysiology of Renovascular Hypertension
  152. Vasoactive hormones in uraemic patients with chronic hypotension
  153. Correspondence
  154. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases
  155. Uraemic medium causes endothelial cell dysfunction characterized by an alteration of the properties of its subendothelial matrix
  156. Reticulated platelets in uremic patients: Effect of hemodialysis and continuous ambulatory peritoneal dialysis
  157. Effect of antihypertensive treatment on the increased β-adrenoceptor density in patients with essential hypertension
  158. Reversible Decrease of Surface ß2-Adrenoceptor Number and Response in Lymphocytes of Patients with Pheochromocytoma
  159. 24 Effect of antihypertensive treatment on increased (??2-adrenoceptor density in patients with essential hypertension
  160. 31 Decreased ??2-adrenoceptor number and responsiveness in patients with phaeochromocytoma
  161. Intracellular calcium mobilization and activation of the Na+/H+exchanger in platelets
  162. Minimal-Change Glomerulopathy and Carcinoma
  163. Recombinant human erythropoietin treatment improves platelet function in uremic patients
  164. Calciphylaxis in a Hemodialysis Patient: Appearance After Parathyroidectomy During a Psoriatic Flare
  165. Arginine Vasopressin Infusion Increases Plasma Levels of Atrial Natriuretic Factor in Humans
  166. Lymphocyte surface beta2-adrenoceptors in essential hypertension
  167. Lymphocyte surface beta2-adrenoceptors in essential hypertension
  168. Tumor Markers in Chronic Renal Failure and Hemodialysis Patients
  169. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa
  170. Ocular and Auditory Toxicity in Hemodialyzed Patients Receiving Desferrioxamine
  171. Lymphocyte β2-Adrenergic Receptors in Essential Hypertension: Studies in Basal Conditions and After Dynamic Exercise
  172. Treatment of Hyperkalaemia in Renal Failure: Salbutamol v. Insulin
  173. Improvement of renal function in azotaemic hypertensive patients after surgical revascularization
  174. Reversal of Renal Failure after Revascularization in Atheromatous Renovascular Disease
  175. A Possible Pathogenic Mechanism for Rhabdomyolysis Associated with Multiple Myeloma
  176. Visceral Involvement of Dialysis Amyloidosis
  177. Thoracic Duct Injury: An Unusual Complication following Subclavian Catheterization for Hemodialysis
  178. UREMIC PLASMA, AFTER INFUSION OF DESMOPRESSIN, IMPROVES THE INTERACTION OF NORMAL PLATELETS WITH VESSEL SUBENDOTHELIUM
  179. Rhabdomyolysis Associated With Pleural Tuberculosis
  180. NIFEDIPINE-INDUCED PAROTITIS